<DOC>
	<DOCNO>NCT00216021</DOCNO>
	<brief_summary>In vitro data suggest synergy oxaliplatin 5-FU . The combination oxaliplatin 5-fluorouracil produce objective response rate range 27-34 % two study patient prior chemotherapy . Capecitabine design orally administer , tumor selective fluoropyrimidine , preferentially convert 5-FU tumor site high level pyrimidine nucleoside phosphorylase ( PyNPase ) tumor tissue compare normal tissue . The end result high concentration 5-fluorouracil tumor relative surround normal tissue . This trial investigate activity novel capecitabine/oxaliplatin ( CAPOX ) combination patient advanced disease . In addition , exploratory analysis correlate response thymidine synthase thymidine phosphorylase expression primary tumor sample .</brief_summary>
	<brief_title>Capecitabine Oxaliplatin Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . CAPOX ( 21 day cycle ) : - Capecitabine 825 mg/m2 orally twice daily Days 1-14 . - Oxaliplatin 100 mg/m2 intravenously Day 1 Patients may continue combination therapy progression toxicity intervenes . Patients discontinue either agent due toxicity may , investigator discretion , continue therapy remain single agent study . ECOG performance status 0 1 Hematopoietic : · - ANC &gt; 1,200/mm3· - Platelets &gt; 100,000/mm3 Hepatic : · - Total bilirubin &lt; 1.5 x ULN· - AST &lt; 2 x ULN ( 5 x ULN patient know liver involvement ) Renal : · - Serum creatinine &lt; 1.5 x ULN estimate creatinine clearance &gt; 50ml/min calculated Cockroft-Gault equation Cardiovascular : · - No clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologic cytologic diagnosis breast cancer evidence ( 1 ) unresectable , locally recurrent , ( 2 ) metastatic disease.· Patients HER2 positive ( 3+ overexpression IHC gene amplification FISH ) eligible prior trastuzumab therapy.· At least one measurable lesion define RECIST . Prior radiation therapy allow long irradiated area source measurable disease . No prior therapy capecitabine oxaliplatin set No prior therapy platinum compounds· No form cancer therapy include radiation , chemotherapy hormonal therapy within 21 day prior begin protocol therapy.· No prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil.· No prior fluoropyrimidine therapy metastatic disease allow . Prior adjuvant fluoropyrimidine therapy allow complete &gt; 12 month study entry.· Maximum one prior chemotherapy regimen unresectable , locally recurrent metastatic disease· No symptomatic brain metastasis . · No evidence serious concomitant systemic disorder incompatible study · No peripheral neuropathy · No major surgery within 28 day prior begin protocol therapy.· Negative pregnancy test· No female patient currently breastfeeding· No malabsorption syndrome· No evidence serious concomitant systemic disorder incompatible study· Patients must treat follow protocol therapy within 28 day prior begin protocol therapy : sorivudine , brivudine , cimetidine , allopurinol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>